Viking Therapeutics (Nasdaq: VKTX) shares rose 35.7% to close at $40.85 on Tuesday. The rally followed new clinical data for VK2735, the company’s experimental weekly…
September 23, 2026
Cytokinetics (NASDAQ: CYTK) shares rocketed 28% Tuesday after the company reported positive topline results from ACACIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten in…
April 22, 2026
Johnson & Johnson Reports Sustained Efficacy of IMAAVY for Generalized Myasthenia Gravis
Johnson & Johnson (NYSE: JNJ) announced new data from its Phase 3 Vivacity-MG3 study, showing that IMAAVY (nipocalimab-aahu) maintains disease control in adults with generalized…
April 14, 2026
AVITA Medical’s Cohealyx Slashes Time to Skin Grafting by Nearly 20 Days in Interim Study
AVITA Medical (NASDAQ: RCEL) has reported a notable advance in wound care, with new interim data showing its Cohealyx dermal matrix dramatically accelerates the path…
Dyne Therapeutics, Inc. (Nasdaq: DYN) has officially initiated the Phase 3 HARMONIA trial for zeleciment basivarsen (z-basivarsen, also known as DYNE-101) ,marking a significant step…
March 09, 2026
Dianthus Therapeutics Stock Rises on Positive Phase 3 Trial Data and Q4 Earnings Report
Dianthus Therapeutics Inc. (NASDAQ:DNTH) saw its shares surge 25.05% in pre-market trading on Monday following significant clinical and financial announcements. The biotechnology company reported its…
November 20, 2025
Plus Therapeutics Expands Market Access for CNSide® Cancer Assay with Humana National Coverage Agreement
Plus Therapeutics, Inc. (Nasdaq: PSTV) has announced a significant expansion in market access for its proprietary CNSide® Cerebrospinal Fluid (CSF) Assay. Through its wholly-owned subsidiary,…
October 27, 2025
Actinium Showcases Groundbreaking Anti-Tumor Efficacy of ATNM-400 in Lung Cancer at AACR-NCI-EORTC Conference
ATNM-400 Outperforms Leading Therapies: Demonstrates 3-5x greater tumor growth inhibition compared to first-line osimertinib (TAGRISSO®), second-line Dato-DXd (DATROWAY®), and third-line amivantamab (RYBREVANT®). Synergistic Combination with…